

Sub E2
10
16. (twice amended) A method of screening substances for a substance for treatment of a disease caused by an aberrant receptor, which has substantially changed affinity for substances, comprising bringing an aberrant receptor into contact with a substance and assaying the operation activity of said substance on said receptor.

Sub E4
13
19. (twice amended) The screening method according to claim 16, wherein the method further comprises the step of selecting the receptor by comparing the gene encoding the aberrant receptor, isolated from a cell of a mammal suffering from a disease caused by the aberrant receptor, with a gene encoding the non-aberrant receptor, prepared from a cell of a mammal of the same species that does not carry the aberrant receptor.

Sub E5
14
21. (amended) A method of preparing a substance for treatment of a disease caused by an aberrant receptor having a substantially changed affinity for substances, which results in the substantial reduction in activity of the signal transduction system of cells having the aberrant receptor, the method comprising:
selecting a substance from subject substances by bringing the aberrant receptor into contact with a subject substance, assaying the activity of said substance on the aberrant receptor,
selecting a substance that substantially operates the signal transduction system of the cell having the aberrant receptor wherein said activity is activity that restores wide-type activity of the receptor
and admixing the selected substance with a pharmaceutically acceptable carrier.

22. (twice amended) The method according to claim 21, wherein the aberrant receptor, which has substantially changed affinity for substances, is isolated from a cell which expresses with the gene encoding the aberrant receptor.

23. (twice amended) The method according to claim 22, wherein the gene encoding the aberrant receptor is selected by comparing the gene encoding the